Skip to main content
Premium Trial:

Request an Annual Quote

Pharmacopeia To Trade Under Accelrys Symbol on Nasdaq

NEW YORK, Feb. 27 (GenomeWeb News) - Pharmacopeia will begin trading on the Nasdaq today under the ticker symbol "ACCL," the company said yesterday. The change comes as Pharmacopeia prepares to take on the name "Accelrys" as part of a planned reorganization that includes the spin-off of its drug discovery unit.


The company announced its spin-off plan in December. Pharmacopeia's drug discovery unit will become a separate company with the name Pharmacopeia Drug Discovery, while the original company will continue to operate the Accerlys software business under the Accelrys name. The company said yesterday that it will request approval of the name change at its upcoming 2004 stockholder meeting. Meanwhile, PPD has applied for a listing on the Nasdaq National Market under the ticker symbol "PCOP."


The spin-off is expected to formally take place by the end of the present quarter, Pharmacopeia said.


The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.